Engage in impactful medical leadership for COPD Biologics, guiding strategic US initiatives across clinical development and post-approval phases to enhance patient outcomes through collaboration and scientific excellence.

Transform patient outcomes by leading US medical strategy for COPD biologics. Drive evidence generation, external engagement, and cross-functional collaboration to enhance medical excellence and launch readiness in pulmonary medicine.

Champion transformative patient care by leading medical strategy for COPD biologics. Drive evidence generation and external engagement while collaborating with teams to align US medical efforts with global goals and clinical needs.

Shape the future of COPD treatment by leading US medical strategy, guiding cross-functional teams, and influencing clinical practice through innovative research and strategic evidence generation for patient-focused solutions.

Tackle advanced pharmaceutical sales by leveraging deep clinical expertise to engage healthcare professionals and drive strategic initiatives, enhancing patient care through innovative solutions in specialized therapeutic areas.